Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years

• Κύριοι συγγραφείς: Andreas Wollenberg (Συγγραφέας), Masanori Ikeda (Συγγραφέας), Chia-Yu Chu (Συγγραφέας), Lawrence F. Eichenfield (Συγγραφέας), Marieke M. B. Seyger (Συγγραφέας), Apurva Prakash (Συγγραφέας), Robinette Angle (Συγγραφέας), Danting Zhu (Συγγραφέας), Marco Pontes (Συγγραφέας), Amy S. Paller (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Background Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS.Objective To assess longer-term efficacy and safety of baricitinib in pediatric patients aged 2...